VEDANTA BIOSCIENCES
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. It includes a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally defined bacterial consortia in powder form to help physicians have access to live bacteria drugs to treat autoimmune and inflammatory diseases easily.
VEDANTA BIOSCIENCES
Industry:
Biotechnology Business Development Medical
Founded:
2010-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.vedantabio.com
Total Employee:
101+
Status:
Active
Contact:
(857)706-1427
Total Funding:
436.99 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving SPF Apple Mobile Web Clips Icon Google Font API Google Analytics Content Delivery Network LetsEncrypt Amazon
Similar Organizations
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
ExpressCells
ExpressCells creates custom cell lines for biological research and drug discovery.
Fauna Bio
Fauna Bio is a biotechnology company leveraging the science of hibernation to improve healthcare for humans.
Pionyr Immunotherapeutics
Pionyr Immunotherapeutics is a developer of cancer immunotherapies designed to target the tumor microenvironment.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Current Advisors List
Board_member
Board_member
Board_member
2015-05-01
Board_member
2023-04-01
Board_member
2023-04-01
Board_member
2020-11-01
Board_member
2023-04-01
Current Employees Featured
Alexander Rudensky Scientific Co-Founder @ Vedanta Biosciences
Scientific Co-Founder
Dan Littman Scientific Co-Founder @ Vedanta Biosciences
Scientific Co-Founder
Bernat Olle CEO, Co-founder & Board of Directors @ Vedanta Biosciences
CEO, Co-founder & Board of Directors
2015-09-01
Ruslan Medzhitov Co-Founder & Chair @ Vedanta Biosciences
Co-Founder & Chair
Daniel Couto Chief Operating Officer @ Vedanta Biosciences
Chief Operating Officer
2019-10-01
Silvia Caballero Director, Infectious Diseases @ Vedanta Biosciences
Director, Infectious Diseases
2021-04-01
Jeffrey Silber CMO @ Vedanta Biosciences
CMO
2020-01-01
Simona Levi Chief Legal Officer @ Vedanta Biosciences
Chief Legal Officer
2021-10-01
Founder
Investors List
CARB-X
CARB-X investment in Grant - Vedanta Biosciences
Colorcon Ventures
Colorcon Ventures investment in Venture Round - Vedanta Biosciences
Fiscus Ventures
Fiscus Ventures investment in Series E - Vedanta Biosciences
PureTech Health
PureTech Health investment in Series E - Vedanta Biosciences
Skyviews Life Science
Skyviews Life Science investment in Series E - Vedanta Biosciences
Atlantic Neptune
Atlantic Neptune investment in Series E - Vedanta Biosciences
Peak 6
Peak 6 investment in Series E - Vedanta Biosciences
AMR Action Fund
AMR Action Fund investment in Series E - Vedanta Biosciences
Revelation Partners
Revelation Partners investment in Series E - Vedanta Biosciences
Korea Investment Holdings
Korea Investment Holdings investment in Series E - Vedanta Biosciences
Key Employee Changes
Official Site Inspections
http://www.vedantabio.com Semrush global rank: 1.1 M Semrush visits lastest month: 25.05 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Vedanta Biosciences"
Vedanta Biosciences, Inc.
Advancing the Treatment of Gastrointestinal Diseases Using Defined Bacterial Consortia. © 2024 Vedanta Biosciences, Inc. All Rights Reserved.See details»
Careers - Vedanta Biosciences, Inc.
We are enabling this new drug class with groundbreaking and industry-leading scientific work powered by large-scale capabilities to identify, screen, and manufacture bacteria with drug-like …See details»
Vedanta Biosciences - Crunchbase Company Profile
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. It includes a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets …See details»
Vedanta Biosciences Company Profile 2024: Valuation, …
Developer of orally delivered defined bacterial consortia designed to treat inflammatory and infectious diseases.See details»
Vedanta Biosciences, Inc. | LinkedIn
Vedanta is developing a novel class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. Vedanta was co-founded by PureTech Health and a...See details»
Vedanta Biosciences Inc - Company Profile and News
The Company design and develops medicines based on consortia of human commensal bacteria to treat a range of gastrointestinal diseases, using insights from microbial ecology, mucosal …See details»
Vedanta Biosciences – Right Partner For Your Chemistry Solutions
Vedanta Biosciences is a Hyderabad based Contract Research Organization (CRO) serving as an outsourcing partner for the biotech, pharmaceutical industries and research institutions. …See details»
Vedanta Biosciences - Overview, News & Similar companies
May 21, 2024 · Vedanta Biosciences contact info: Phone number: (857) 706-1427 Website: www.vedantabio.com What does Vedanta Biosciences do? Founded in 2010, Vedanta …See details»
Vedanta Biosciences Announces $25 Million Investment from …
CAMBRIDGE, January 12, 2021 – Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally …See details»
Vedanta Biosciences - Craft
Vedanta Biosciences was founded by PureTech and a team of world renowned experts in immunology and microbiology. Vedanta Biosciences is developing a class of drugs that work …See details»
Vedanta Biosciences CEO and Key Executive Team | Craft.co
Vedanta Biosciences's key executives include Bernat Olle and 16 others. Need Data? Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via …See details»
Vedanta Biosciences - VentureRadar
"Vedanta Biosciences is a clinical-stage microbiome leader developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human …See details»
Vedanta Biosciences - Work in biotech
Vedanta has one of the largest, most diverse culture collections of gut bacteria in the world and is using their discovery platform to identify defined bacterial consortia with drug-like properties …See details»
Vedanta Biosciences Announces Initiation of First-in-Patient Study …
CAMBRIDGE, Mass., Dec. 10, 2019 — Vedanta Biosciences, Inc. (Vedanta Biosciences, Vedanta or the Company), a clinical-stage biopharmaceutical company developing a new category of …See details»
Vedanta Biosciences Announces First Patient Dosed in Phase 2 …
Oct 4, 2023 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined …See details»
Vedanta Biosciences Announces $25 Million Investment from
Jan 12, 2021 · CAMBRIDGE, Mass. -- (BUSINESS WIRE)-- Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases …See details»
Working at Vedanta biosciences - Glassdoor
Mission: We believe that in the near future, doctors will have an entirely new option to treat patients: bacterial consortia therapeutics. We are enabling this new drug class with …See details»
Press Releases :: Vedanta Biosciences, Inc.
Oct 16, 2024 · Oct 11, 2023 Vedanta Biosciences Presents Progress from Two Defined Bacterial Consortia, VE303 for the Prevention of C. difficile and VE707 for the Prevention of Gram …See details»
Vedanta Biosciences Completes $68 Million Series D Financing
Jul 21, 2021 · Vedanta has received funding from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) of up to $7.4 million, plus up to $3.5 million more if …See details»
Product Engine :: Vedanta Biosciences, Inc.
Our field-leading product engine enables identification of defined bacterial consortia with drug-like properties and their manufacture to CGMP standards. Gut dysbiosis is a known driver of …See details»